Xelpros is indicated in the treatment of open-angle glaucoma or ocular hypertension. Sun Pharma in-licensed Xelpros from SPARC in June 2015 and the USFDA approval triggered a milestone payment of $10mn to SPARC. Further, with Xelpros sales kicking in, SPARC will also receive sales royalties going forward.
This is the second NDA approval for SPARC’s R&D pipeline. For Sun Pharma, this is a good start for the year. Last year, the company received USFDA EIR for its Halol facility after years of struggle and received an Elepsia approval in December 2018.
Sun is trying to build up its specialty products in dermatology, oncology, and ophthalmology in the US and has several products lined up for launches going ahead.
|Absorica||Acne||Already launched: Nearing patent expiry|
|Levulan Kerastick||Actinic Keratose||Already launched: Nearing patent expiry|
|Elepsia XR||Epilepsy||Approved in December 2018|
|Cequa||Dry Eye||Approved in August 2018|
|Illumya||Epilepsy||Approved in March 2018; launched in October 2018|
|Bromsite||Eye care||Launched in November 2016|
|Kapspargo Sprinkle||Heart failure||Launched in August 2018|
|Yonsa||Prostate Cancer||Approved in May 2018|
|Odomzo||Basal Cell Carcinoma||Bought from Novartis in December 2016|
|Seciera||Dry Eye||Currently in Phase trials|